GeneCentric Therapeutics/Tempus PurIST Pancreatic Cancer Test

GeneCentric Therapeutics' PurIST test for pancreatic cancer is now commercially available through Tempus for clinical use. PurIST is an RNA-expression test for identifying those patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) most likely to experience longer overall survival with standard-of-care FOLFIRINOX than patients with the basal PDAC subtype. PurIST is a laboratory-developed test validated by Tempus as part of its whole-transcriptome RNA sequencing platform.